Table 1. Baseline characteristics for cohort of patients with 1 – 3 months (n = 1,029) and 4 – 6 months (n = 424) of SO prescription.
| Baseline characteristics | Cohort with 1 – 3 months of SO prescription | Cohort with 4 – 6 months of SO prescription |
|---|---|---|
| Number of patients | 1,029 | 424 |
| Age, years | 52.4 ± 13.0 | 51.2 ± 12.9 |
| BMI, kg/m2 | 32.3 ± 8.8 | 32.3 ± 9.1 |
| Time from first dialysis, months | 53.3 ± 46.7 | 55.9 ± 49.1 |
| Male, n (%) | 555 (53.9) | 240 (56.6) |
| Race, n (%) | ||
| White | 522 (50.7) | 204 (48.1) |
| Black/African American | 452 (43.9) | 195 (46) |
| Other | 55 (5.4) | 25 (5.9) |
| Hispanic/Latino, n (%) | 163 (15.8) | 71 (16.8) |
| Comorbidities, n (%) | ||
| Diabetes mellitus | 605 (58.8) | 246 (58) |
| Congestive heart failure | 215 (20.9) | 80 (18.9) |
| Reason for ESRD, n (%) | ||
| Hypertension | 338 (32.9) | 143 (33.7) |
| Diabetes mellitus | 428 (41.6) | 171 (40.3) |
| Glomerulonephritis | 43 (4.1) | 15 (3.6) |
| Other | 220 (21.4) | 95 (22.4) |
| Baseline phosphate binder, n (%) | ||
| Calcium acetate | 242 (23.5) | 94 (22.2) |
| Sevelamer | 629 (61.1) | 269 (63.4) |
| Lanthanum carbonate | 72 (7) | 32 (7.6) |
| Recorded switch between phosphate binders | 86 (8.4) | 29 (6.8) |
| Anemia therapy, n (%) | ||
| IV iron usea | 810 (78.7) | 331 (78.1) |
| ESA useb | 879 (84.6) | 353 (83.3) |
Values are expressed as mean ± SD or number (%) of patients. aIV iron treatment includes iron sucrose, ferumoxytol, and sodium ferric gluconate; bESA treatment includes epoetin-α, epoetin-β and methoxy polyethylene glycol, and darbepoetin-α; BMI = body mass index; ESA = erythropoiesis stimulating agent; ESRD = end stage renal disease; IV = intravenous; SO = sucroferric oxyhydroxide.